CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of gastrointestinal cancers.
  
  LEARNING OBJECTIVES

  • Summarize studies analyzing the associations between biomarkers and outcomes with adjuvant treatment for patients with operable colorectal cancer (CRC).
  • Develop a long-term plan to guide the selection and sequencing of therapies for patients diagnosed with metastatic CRC, considering their biomarker profile, tumor location, prior systemic therapy, symptomatology and personal goals of treatment.
  • Use HER2 status, PD-L1 combined positive score and other clinical and biologic factors to optimize the selection and sequence of systemic therapy for patients with gastric, gastroesophageal junction and esophageal cancers.
  • Consider patient age, performance status, degree of liver function and other clinical factors in the selection of first- and later-line therapy for unresectable or metastatic hepatocellular carcinoma.
  • Recall clinical trial data with approved and investigational systemic interventions for patients with localized, locally advanced or metastatic pancreatic adenocarcinoma, and establish an evidence-based approach to selecting therapy.
  • Discuss the biologic justification for the evaluation of immune checkpoint inhibitors in patients with advanced biliary tract cancers, and review available data with anti-PD-1/PD-L1 antibody-based approaches.
  • Recognize the molecular heterogeneity of biliary tract cancers, and appreciate the biologic rationale for utilizing documented molecular abnormalities in treatment decision-making.
  • Appraise available and emerging data with investigational agents currently in clinical testing for gastrointestinal cancers.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  Presentations Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Rachna T Shroff, MD, MS
  Interim Chief Division of Hematology/Oncology
  Chief, Section of GI Medical Oncology
  Associate Director of Clinical Investigations, UACC
  Associate Dean, Clinical and Translational Research, UA-COM
  Associate Professor of Medicine
  University of Arizona Cancer Center (UACC)
  University of Arizona College of Medicine – Tucson (UA-COM)
  Tucson, Arizona
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Genentech, a member of the Roche Group, Incyte Corporation, Merck, QED Therapeutics, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc, Zymeworks Inc; Consulting Agreement: Syros Pharmaceuticals Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Exelixis Inc, IMV Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, NuCana, Pieris Pharmaceuticals Inc, QED Therapeutics, Rafael Pharmaceuticals Inc, Seagen Inc, Taiho Oncology Inc.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Astellas, Merck, and Taiho Oncology Inc.
  
  Release date: November 2022
  Expiration date: November 2023